JP2015525762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525762A5 JP2015525762A5 JP2015521742A JP2015521742A JP2015525762A5 JP 2015525762 A5 JP2015525762 A5 JP 2015525762A5 JP 2015521742 A JP2015521742 A JP 2015521742A JP 2015521742 A JP2015521742 A JP 2015521742A JP 2015525762 A5 JP2015525762 A5 JP 2015525762A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- etanercept
- stabilized
- less
- stabilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 16
- 108010008165 Etanercept Proteins 0.000 claims 10
- 229960000403 etanercept Drugs 0.000 claims 10
- 239000003381 stabilizer Substances 0.000 claims 9
- 229930006000 Sucrose Natural products 0.000 claims 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- 239000005720 sucrose Substances 0.000 claims 8
- 239000001488 sodium phosphate Substances 0.000 claims 7
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 7
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 6
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 4
- 229960003194 meglumine Drugs 0.000 claims 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 4
- 239000000811 xylitol Substances 0.000 claims 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 4
- 229960002675 xylitol Drugs 0.000 claims 4
- 235000010447 xylitol Nutrition 0.000 claims 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 239000001110 calcium chloride Substances 0.000 claims 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 229930195712 glutamate Natural products 0.000 claims 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 238000013467 fragmentation Methods 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000011592 zinc chloride Substances 0.000 claims 1
- 235000005074 zinc chloride Nutrition 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261669480P | 2012-07-09 | 2012-07-09 | |
| US61/669,480 | 2012-07-09 | ||
| US201361806235P | 2013-03-28 | 2013-03-28 | |
| US61/806,235 | 2013-03-28 | ||
| PCT/US2013/049716 WO2014011629A1 (en) | 2012-07-09 | 2013-07-09 | Stable aqueous formulations of etanercept |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015525762A JP2015525762A (ja) | 2015-09-07 |
| JP2015525762A5 true JP2015525762A5 (enExample) | 2016-09-01 |
Family
ID=49916504
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521752A Expired - Fee Related JP6271536B2 (ja) | 2012-07-09 | 2013-07-09 | 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤 |
| JP2015521742A Pending JP2015525762A (ja) | 2012-07-09 | 2013-07-09 | エタネルセプトの安定な水性製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521752A Expired - Fee Related JP6271536B2 (ja) | 2012-07-09 | 2013-07-09 | 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10822429B2 (enExample) |
| EP (2) | EP2869817A4 (enExample) |
| JP (2) | JP6271536B2 (enExample) |
| KR (1) | KR20150030704A (enExample) |
| CN (1) | CN104661651A (enExample) |
| AU (1) | AU2013290289B2 (enExample) |
| BR (2) | BR112015000203A2 (enExample) |
| CA (1) | CA2878508A1 (enExample) |
| CL (1) | CL2015000051A1 (enExample) |
| DO (1) | DOP2015000006A (enExample) |
| EA (1) | EA029193B1 (enExample) |
| EC (1) | ECSP15004752A (enExample) |
| HK (2) | HK1209343A1 (enExample) |
| IL (1) | IL236527A0 (enExample) |
| IN (1) | IN2015KN00005A (enExample) |
| MX (1) | MX2015000337A (enExample) |
| PE (1) | PE20150762A1 (enExample) |
| SG (1) | SG11201500138VA (enExample) |
| WO (2) | WO2014011629A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| SI2895188T1 (en) * | 2012-09-11 | 2018-05-31 | Coherus Biosciences, Inc. | CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE |
| CN105873601A (zh) * | 2013-05-02 | 2016-08-17 | 马柏克辛斯公司 | TNFR:Fc融合多肽的替代配方 |
| RU2715236C2 (ru) | 2014-03-26 | 2020-02-26 | Астекс Терапьютикс Лтд | Комбинации |
| JP6781508B2 (ja) * | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| MX389818B (es) * | 2015-08-13 | 2025-03-20 | Landsteiner Scient S A De C V | Composicion de estabilidad mejorada de etanercept. |
| US11324829B2 (en) * | 2016-03-14 | 2022-05-10 | Santen Pharmaceutical Co., Ltd. | Antiseptic agent comprising meglumine or salt thereof |
| PT3528787T (pt) | 2016-10-21 | 2026-03-11 | Amgen Inc | Formulações farmacêuticas e métodos para produzir as mesmas |
| JP7116059B2 (ja) * | 2016-11-21 | 2022-08-09 | ジャスト－エヴォテック バイオロジックス、インコーポレイテッド | アフリベルセプト製剤及びその使用 |
| MX2017013995A (es) * | 2017-10-31 | 2019-05-01 | Probiomed S A De C V | Formulacion farmaceutica estable de una proteina de fusion. |
| US20200323958A1 (en) * | 2017-11-13 | 2020-10-15 | Amgen Inc. | Methods for producing protein products |
| AU2019254478A1 (en) * | 2018-04-16 | 2020-12-03 | Merck Patent Gmbh | Method for stabilizing protein comprising formulations by using a meglumine salt. |
| AU2019260418B2 (en) * | 2018-04-24 | 2024-12-12 | Amgen Inc. | Method for making injectable pharmaceutical compositions |
| US11253569B2 (en) | 2018-05-03 | 2022-02-22 | Seattle Children's Hospital | Methods of treating Kawasaki Disease |
| TR201808283A2 (tr) * | 2018-06-11 | 2018-07-23 | Centurion Ilac San Ve Tic A S | Sulu farmasöti̇k etenersept bi̇leşi̇mi̇ |
| GB201911461D0 (en) | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
| JP7721516B2 (ja) * | 2019-10-28 | 2025-08-12 | アストラゼネカ・アクチエボラーグ | ロイシン及びトリロイシンを含む乾燥粉末製剤 |
| US20240166718A1 (en) | 2021-02-17 | 2024-05-23 | Arecor Limited | Aqueous composition of an engineered protein construct comprising an fc domain |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| EP1171148A2 (en) | 1999-04-19 | 2002-01-16 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical desorders |
| EP1261364A1 (en) | 2000-02-10 | 2002-12-04 | Wyeth | Method of treating or inhibiting cellular injury or cell death |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| SI1478394T1 (sl) * | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| JP4980048B2 (ja) | 2003-02-28 | 2012-07-18 | アレス トレーディング ソシエテ アノニム | 腫瘍壊死因子結合タンパク質の液体製剤 |
| US20060177444A1 (en) | 2003-03-20 | 2006-08-10 | Tatsuo Horizoe | Concomitant drug as therapeutic agent for inflammatory bowel disease |
| BRPI0413197A (pt) | 2003-08-01 | 2006-10-03 | Amgen Inc | cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept |
| WO2005037214A2 (en) * | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
| WO2005082377A1 (ja) | 2004-03-01 | 2005-09-09 | Ajinomoto Co., Inc. | 抗ヒトTNF-α抗体活性低下抑制剤 |
| CA2557046A1 (en) | 2004-03-05 | 2005-10-13 | John Crowley | Process for cell culturing by continuous perfusion and alternating tangential flow |
| US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| KR101367544B1 (ko) | 2005-06-10 | 2014-02-26 | 추가이 세이야쿠 가부시키가이샤 | 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용 |
| US8476239B2 (en) * | 2005-12-20 | 2013-07-02 | Bristol-Myers Squibb Company | Stable protein formulations |
| BRPI0620316A2 (pt) | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| AU2007240732B2 (en) | 2006-04-21 | 2013-07-04 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
| TW200831129A (en) * | 2006-10-06 | 2008-08-01 | Amgen Inc | Stable formulations |
| EP2094247B1 (en) * | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
| ES2541546T3 (es) | 2006-11-03 | 2015-07-21 | Wyeth Llc | Sustancias que inhiben la glucólisis en cultivo celular |
| CA2790018C (en) | 2006-12-21 | 2015-02-03 | Amgen Inc. | Formulations |
| AU2008223133A1 (en) | 2007-03-02 | 2008-09-12 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
| EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
| NZ595526A (en) | 2007-06-14 | 2013-03-28 | Biogen Idec Inc | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| AU2009210741A1 (en) * | 2008-02-07 | 2009-08-13 | Amgen Inc. | Stabilized protein compositions |
| BRPI0908270A2 (pt) | 2008-02-29 | 2019-09-10 | Biogen Idec Inc | proteínas de fusão de imunoglobulinas purificadas e método para a sua purificação |
| PT2331090T (pt) * | 2008-09-19 | 2018-02-07 | Pfizer | Formulação de anticorpo líquida estável |
| WO2011015926A1 (en) | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein |
| HRP20200768T4 (hr) | 2009-08-11 | 2025-03-28 | F. Hoffmann - La Roche Ag | Proizvodnja proteina u mediju za uzgoj stanica bez glutamina |
| EP2490780A4 (en) | 2009-10-20 | 2014-04-09 | Merck Sharp & Dohme | USE OF A MIXED MODE CHROMATOGRAPHY FOR THE DETECTION AND PURIFICATION OF BASIC ANTIBODY PRODUCTS |
| WO2011079308A2 (en) | 2009-12-23 | 2011-06-30 | Emergent Product Development Seattle, Llc | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| CA2797356C (en) | 2010-04-26 | 2020-12-29 | Novartis Ag | Improved cell culture medium |
| CN102946858B (zh) * | 2010-05-10 | 2015-09-30 | 英塔斯制药有限公司 | 含有免疫球蛋白Fc的多肽的液体制剂 |
| EP2598167B1 (en) * | 2010-07-30 | 2015-04-01 | Arecor Limited | Stabilized aqueous antibody compositions |
| JP2013535981A (ja) | 2010-08-20 | 2013-09-19 | ワイス・エルエルシー | 成長因子不含適合細胞の細胞培養 |
| JP2012049074A (ja) | 2010-08-30 | 2012-03-08 | Makita Corp | 電動工具のバッテリパック |
| AU2011296702A1 (en) | 2010-08-31 | 2013-03-21 | Friesland Brands B.V. | Culture medium for eukaryotic cells |
| EP2699265B1 (en) * | 2011-04-20 | 2019-10-16 | Sandoz AG | STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc |
| UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| PT2837680T (pt) | 2011-07-01 | 2020-04-17 | Amgen Inc | Cultura celular de mamífero |
| CN103930124B (zh) | 2011-07-01 | 2021-05-11 | 生物基因Ma公司 | 无精氨酸的tnfr：fc-融合多肽组合物及使用方法 |
| BR112014009146A8 (pt) * | 2011-10-18 | 2017-06-20 | Coherus Biosciences Inc | formulações de etanercepte estabilizadas com aminoácidos |
-
2013
- 2013-07-09 HK HK15110117.0A patent/HK1209343A1/xx unknown
- 2013-07-09 JP JP2015521752A patent/JP6271536B2/ja not_active Expired - Fee Related
- 2013-07-09 SG SG11201500138VA patent/SG11201500138VA/en unknown
- 2013-07-09 CA CA2878508A patent/CA2878508A1/en not_active Abandoned
- 2013-07-09 JP JP2015521742A patent/JP2015525762A/ja active Pending
- 2013-07-09 BR BR112015000203A patent/BR112015000203A2/pt not_active IP Right Cessation
- 2013-07-09 KR KR1020157000510A patent/KR20150030704A/ko not_active Withdrawn
- 2013-07-09 AU AU2013290289A patent/AU2013290289B2/en not_active Expired - Fee Related
- 2013-07-09 CN CN201380046666.4A patent/CN104661651A/zh active Pending
- 2013-07-09 MX MX2015000337A patent/MX2015000337A/es unknown
- 2013-07-09 WO PCT/US2013/049716 patent/WO2014011629A1/en not_active Ceased
- 2013-07-09 EP EP13817186.3A patent/EP2869817A4/en not_active Withdrawn
- 2013-07-09 BR BR112015000229A patent/BR112015000229A2/pt not_active IP Right Cessation
- 2013-07-09 IN IN5KON2015 patent/IN2015KN00005A/en unknown
- 2013-07-09 PE PE2015000026A patent/PE20150762A1/es not_active Application Discontinuation
- 2013-07-09 WO PCT/US2013/049778 patent/WO2014011672A1/en not_active Ceased
- 2013-07-09 HK HK15110120.5A patent/HK1213174A1/zh unknown
- 2013-07-09 EA EA201590161A patent/EA029193B1/ru not_active IP Right Cessation
- 2013-07-09 EP EP13816429.8A patent/EP2869816A4/en not_active Withdrawn
-
2014
- 2014-12-31 IL IL236527A patent/IL236527A0/en unknown
-
2015
- 2015-01-08 US US14/592,569 patent/US10822429B2/en not_active Expired - Fee Related
- 2015-01-08 US US14/592,654 patent/US9662396B2/en not_active Expired - Fee Related
- 2015-01-08 CL CL2015000051A patent/CL2015000051A1/es unknown
- 2015-01-09 DO DO2015000006A patent/DOP2015000006A/es unknown
- 2015-02-09 EC ECIEPI20154752A patent/ECSP15004752A/es unknown
-
2020
- 2020-09-28 US US17/034,134 patent/US20210007991A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015525762A5 (enExample) | ||
| JP2015527402A5 (enExample) | ||
| JP2015525763A5 (enExample) | ||
| BR112014009131A2 (pt) | formulações de etanercept estabilizadas com meglumina | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| MX384836B (es) | Agentes antivirales contra la hepatitis b | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| WO2016095013A8 (en) | Pharmaceutical composition comprising plasminogen and uses thereof | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| BR112014029006A2 (pt) | derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral | |
| JP2014218522A5 (enExample) | ||
| JP2013520405A5 (enExample) | ||
| JP2009531457A5 (enExample) | ||
| EA033396B1 (ru) | Быстродействующие инсулиновые композиции | |
| EA201691322A1 (ru) | Фармацевтическая композиция ингибитора dpp-iv в комбинации с метформином | |
| RU2019138024A (ru) | ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9c, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| EA201490175A1 (ru) | Составы дезоксихолевой кислоты и ее солей | |
| BR112017023720A2 (pt) | formulações de inibidor de corrosão | |
| PH12015502802A1 (en) | Formulation comprising a hypolipidemic agent | |
| EA201890771A1 (ru) | Соли и твердые формы монобактамного антибиотика | |
| JP2022514597A5 (enExample) | ||
| HRP20190783T1 (hr) | Farmaceutske formulacije | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| JP2019513138A5 (enExample) | ||
| EA201691825A1 (ru) | Стабилизированный раствор на основе активных веществ, способ получения стабилизированного раствора активных веществ, фармацевтическая композиция на основе стабилизированного раствора активных веществ (два варианта) |